Using the BioAssay Ontology for analyzing high-throughput screening data

Linda Zander Balderud, David Murray, Niklas Larsson, Uma Vempati, Stephan C Schuerer, Marcus Bjäreland, Ola Engkvist

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

High-throughput screening (HTS) is the main starting point for hit identification in drug discovery programs. This has led to a rapid increase of available screening data both within pharmaceutical companies and the public domain. We have used the BioAssay Ontology (BAO) 2.0 for assay annotation within AstraZeneca to enable comparison with external HTS methods. The annotated assays have been analyzed to identify technology gaps, evaluate new methods, verify active hits, and compare compound activity between in-house and PubChem assays. As an example, the binding of a fluorescent ligand to formyl peptide receptor 1 (FPR1, involved in inflammation, for example) in an in-house HTS was measured by fluorescence intensity. In total, 155 active compounds were also tested in an external ligand binding flow cytometry assay, a method not used for in-house HTS detection. Twelve percent of the 155 compounds were found active in both assays. By the annotation of assay protocols using BAO terms, internal and external assays can easily be identified and method comparison facilitated. They can be used to evaluate the effectiveness of different assay methods, design appropriate confirmatory and counterassays, and analyze the activity of compounds for identification of technology artifacts.

Original languageEnglish
Pages (from-to)402-415
Number of pages14
JournalJournal of Biomolecular Screening
Volume20
Issue number3
DOIs
StatePublished - Mar 25 2015

Fingerprint

Bioassay
Biological Assay
Ontology
Assays
Screening
Throughput
Formyl Peptide Receptor
High-Throughput Screening Assays
Ligands
Technology
Public Sector
Drug Discovery
Artifacts
Flow Cytometry
Fluorescence
Inflammation
Flow cytometry
Pharmaceutical Preparations
Network protocols

Keywords

  • assay design
  • BioAssay Ontology
  • detection technology
  • high-throughput screening
  • PubChem

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Pharmacology
  • Biochemistry
  • Molecular Medicine
  • Biotechnology

Cite this

Zander Balderud, L., Murray, D., Larsson, N., Vempati, U., Schuerer, S. C., Bjäreland, M., & Engkvist, O. (2015). Using the BioAssay Ontology for analyzing high-throughput screening data. Journal of Biomolecular Screening, 20(3), 402-415. https://doi.org/10.1177/1087057114563493

Using the BioAssay Ontology for analyzing high-throughput screening data. / Zander Balderud, Linda; Murray, David; Larsson, Niklas; Vempati, Uma; Schuerer, Stephan C; Bjäreland, Marcus; Engkvist, Ola.

In: Journal of Biomolecular Screening, Vol. 20, No. 3, 25.03.2015, p. 402-415.

Research output: Contribution to journalArticle

Zander Balderud, L, Murray, D, Larsson, N, Vempati, U, Schuerer, SC, Bjäreland, M & Engkvist, O 2015, 'Using the BioAssay Ontology for analyzing high-throughput screening data', Journal of Biomolecular Screening, vol. 20, no. 3, pp. 402-415. https://doi.org/10.1177/1087057114563493
Zander Balderud, Linda ; Murray, David ; Larsson, Niklas ; Vempati, Uma ; Schuerer, Stephan C ; Bjäreland, Marcus ; Engkvist, Ola. / Using the BioAssay Ontology for analyzing high-throughput screening data. In: Journal of Biomolecular Screening. 2015 ; Vol. 20, No. 3. pp. 402-415.
@article{4722c9ac79ca47a2a592fed9897eff43,
title = "Using the BioAssay Ontology for analyzing high-throughput screening data",
abstract = "High-throughput screening (HTS) is the main starting point for hit identification in drug discovery programs. This has led to a rapid increase of available screening data both within pharmaceutical companies and the public domain. We have used the BioAssay Ontology (BAO) 2.0 for assay annotation within AstraZeneca to enable comparison with external HTS methods. The annotated assays have been analyzed to identify technology gaps, evaluate new methods, verify active hits, and compare compound activity between in-house and PubChem assays. As an example, the binding of a fluorescent ligand to formyl peptide receptor 1 (FPR1, involved in inflammation, for example) in an in-house HTS was measured by fluorescence intensity. In total, 155 active compounds were also tested in an external ligand binding flow cytometry assay, a method not used for in-house HTS detection. Twelve percent of the 155 compounds were found active in both assays. By the annotation of assay protocols using BAO terms, internal and external assays can easily be identified and method comparison facilitated. They can be used to evaluate the effectiveness of different assay methods, design appropriate confirmatory and counterassays, and analyze the activity of compounds for identification of technology artifacts.",
keywords = "assay design, BioAssay Ontology, detection technology, high-throughput screening, PubChem",
author = "{Zander Balderud}, Linda and David Murray and Niklas Larsson and Uma Vempati and Schuerer, {Stephan C} and Marcus Bj{\"a}reland and Ola Engkvist",
year = "2015",
month = "3",
day = "25",
doi = "10.1177/1087057114563493",
language = "English",
volume = "20",
pages = "402--415",
journal = "Journal of Biomolecular Screening",
issn = "1087-0571",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Using the BioAssay Ontology for analyzing high-throughput screening data

AU - Zander Balderud, Linda

AU - Murray, David

AU - Larsson, Niklas

AU - Vempati, Uma

AU - Schuerer, Stephan C

AU - Bjäreland, Marcus

AU - Engkvist, Ola

PY - 2015/3/25

Y1 - 2015/3/25

N2 - High-throughput screening (HTS) is the main starting point for hit identification in drug discovery programs. This has led to a rapid increase of available screening data both within pharmaceutical companies and the public domain. We have used the BioAssay Ontology (BAO) 2.0 for assay annotation within AstraZeneca to enable comparison with external HTS methods. The annotated assays have been analyzed to identify technology gaps, evaluate new methods, verify active hits, and compare compound activity between in-house and PubChem assays. As an example, the binding of a fluorescent ligand to formyl peptide receptor 1 (FPR1, involved in inflammation, for example) in an in-house HTS was measured by fluorescence intensity. In total, 155 active compounds were also tested in an external ligand binding flow cytometry assay, a method not used for in-house HTS detection. Twelve percent of the 155 compounds were found active in both assays. By the annotation of assay protocols using BAO terms, internal and external assays can easily be identified and method comparison facilitated. They can be used to evaluate the effectiveness of different assay methods, design appropriate confirmatory and counterassays, and analyze the activity of compounds for identification of technology artifacts.

AB - High-throughput screening (HTS) is the main starting point for hit identification in drug discovery programs. This has led to a rapid increase of available screening data both within pharmaceutical companies and the public domain. We have used the BioAssay Ontology (BAO) 2.0 for assay annotation within AstraZeneca to enable comparison with external HTS methods. The annotated assays have been analyzed to identify technology gaps, evaluate new methods, verify active hits, and compare compound activity between in-house and PubChem assays. As an example, the binding of a fluorescent ligand to formyl peptide receptor 1 (FPR1, involved in inflammation, for example) in an in-house HTS was measured by fluorescence intensity. In total, 155 active compounds were also tested in an external ligand binding flow cytometry assay, a method not used for in-house HTS detection. Twelve percent of the 155 compounds were found active in both assays. By the annotation of assay protocols using BAO terms, internal and external assays can easily be identified and method comparison facilitated. They can be used to evaluate the effectiveness of different assay methods, design appropriate confirmatory and counterassays, and analyze the activity of compounds for identification of technology artifacts.

KW - assay design

KW - BioAssay Ontology

KW - detection technology

KW - high-throughput screening

KW - PubChem

UR - http://www.scopus.com/inward/record.url?scp=84923321946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923321946&partnerID=8YFLogxK

U2 - 10.1177/1087057114563493

DO - 10.1177/1087057114563493

M3 - Article

C2 - 25512330

AN - SCOPUS:84923321946

VL - 20

SP - 402

EP - 415

JO - Journal of Biomolecular Screening

JF - Journal of Biomolecular Screening

SN - 1087-0571

IS - 3

ER -